Cargando…

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study

OBJECTIVES: To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes using a prospective cohort of maintenance hemodialysis patients. METHODS: We used data from a prospective cohort of Japanese hemodialysis patients with secondary hyperparathyroidism and exa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asada, Shinji, Yoshida, Kazuki, Fukuma, Shingo, Nomura, Takanobu, Wada, Michihito, Onishi, Yoshihiro, Kurita, Noriaki, Fukagawa, Masafumi, Fukuhara, Shunichi, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541241/ https://www.ncbi.nlm.nih.gov/pubmed/31141505 http://dx.doi.org/10.1371/journal.pone.0216399

Ejemplares similares

Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan
por: Fukuma, Shingo, et al.
Publicado: (2013)

Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2020)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism
por: Kato, Chihiro, et al.
Publicado: (2020)

Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study
por: Tanaka, Motoko, et al.
Publicado: (2016)

Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study
por: Kurita, Noriaki, et al.
Publicado: (2015)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
por: Ogata, Hiroaki, et al.
Publicado: (2017)

Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
por: Tokumoto, Masanori, et al.
Publicado: (2022)

Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study
por: Fukuma, Shingo, et al.
Publicado: (2019)

Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients
por: Yamamoto, Suguru, et al.
Publicado: (2015)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan
por: Fukuma, Shingo, et al.
Publicado: (2017)

Association of coping strategies with mortality and health-related quality of life in hemodialysis patients: The Japan Dialysis Outcomes and Practice Patterns Study
por: Niihata, Kakuya, et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Length of hospital stay is associated with a decline in activities of daily living in hemodialysis patients: a prospective cohort study
por: Kamitani, Tsukasa, et al.
Publicado: (2020)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Development and validation of a prediction model for loss of physical function in elderly hemodialysis patients
por: Fukuma, Shingo, et al.
Publicado: (2018)

Dialysis‐related practice patterns among hemodialysis patients with cancer
por: Nishiwaki, Hiroki, et al.
Publicado: (2018)

Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation
por: Shoji, Tetsuo, et al.
Publicado: (2016)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

A Japanese approach for CKD-MBD
por: Yokoyama, Keitaro, et al.
Publicado: (2013)

Associations of employment status and educational levels with mortality and hospitalization in the dialysis outcomes and practice patterns study in Japan
por: Imanishi, Yasuo, et al.
Publicado: (2017)

Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties
por: Wakamatsu, Takuya, et al.
Publicado: (2020)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Association of advanced glycation end-product accumulation with overactive bladder in community-dwelling elderly: A cross-sectional Sukagawa study
por: Omae, Kenji, et al.
Publicado: (2021)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hvnpff02qiaoe2930f469altdp